HAMILTON, BERMUDA / ACCESS Newswire / January 23, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company…
FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or…
Partnership adds a travel-focused consumer telehealth platform to the ARAKODA® marketing strategy, offering a new convenience to people planning travel…
PARIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene…
Accelerates expansion of BioStem’s commercial organization through integration of an experienced national sales force Expands access to major GPO networks,…
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate…
Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE)…
First commercially available products using AMSilk’s biotech silk protein yarnsDemonstrating a scalable, low impact alternative to conventional silk within luxury…
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the…
Jurek Kozyra, CEO of Nanovery, joins host Karla Jo Helms on the Disruption Interruption podcast to discuss revolutionizing molecular medicine.…